Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Dow
Farmers Insurance
Chinese Patent Office
Boehringer Ingelheim
Federal Trade Commission
Fish and Richardson
US Army
Cipla
Moodys

Generated: October 21, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,855,703

« Back to Dashboard

Which drugs does patent 6,855,703 protect, and when does it expire?


Patent 6,855,703 protects ENJUVIA and is included in one NDA.

This patent has eleven patent family members in seven countries.

This patent has expired prematurely due to non-payment of maintenance fees. See details below.

Summary for Patent: 6,855,703

Title: Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds
Abstract:A composition of matter is provided having a mixture of active estrogenic compounds. The mixture is present in chemically pure form. The mixture includes salts of conjugated estrone, conjugated equilin, conjugated .DELTA..sup.8,9 -dehydroestrone, conjugated 17.alpha.-estradiol, conjugated 17.alpha.-dihydroequilin, conjugated 17.beta.-dihydroequilin, conjugated 17.beta.-estradiol, conjugated equilenin, conjugated 17.alpha.-dihydroequilenin, and conjugated 17.beta.-dihydroequilenin. The mixture also contains the same essential estrogenic compounds present in naturally derived equine conjugated estrogens. Drug products including the composition of matter are also provided, as are methods of using these drug products to treat mammals in need of treatment. Methods of analyzing mixtures containing conjugated estrogens are also provided.
Inventor(s): Hill; Edward N. (Wilmington, NC), Leonard; Thomas W. (Wilmington, NC), Sancilio; Frederick D. (Wilmington, NC), Schlipp; Katherin M. (Wilmington, NC), Shirazi; Dean G. (Wilmington, NC), Whittle; Robert R. (Wilmington, NC)
Assignee: Endeavor Pharmaceuticals (Wilmington, NC)
Application Number:09/524,132
Patent Claim Types:
see list of patent claims
Composition; Use; Formulation;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Teva Branded Pharm
ENJUVIA
estrogens, conjugated synthetic b
TABLET;ORAL021443-001Dec 20, 2004DISCNNoNo► Subscribe► SubscribeYY TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE
Teva Branded Pharm
ENJUVIA
estrogens, conjugated synthetic b
TABLET;ORAL021443-001Dec 20, 2004DISCNNoNo► Subscribe► SubscribeYY TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE
Teva Branded Pharm
ENJUVIA
estrogens, conjugated synthetic b
TABLET;ORAL021443-002Dec 20, 2004DISCNNoNo► Subscribe► SubscribeYY TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE
Teva Branded Pharm
ENJUVIA
estrogens, conjugated synthetic b
TABLET;ORAL021443-002Dec 20, 2004DISCNNoNo► Subscribe► SubscribeYY TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE
Teva Branded Pharm
ENJUVIA
estrogens, conjugated synthetic b
TABLET;ORAL021443-003May 10, 2004DISCNNoNo► Subscribe► SubscribeYY TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE
Teva Branded Pharm
ENJUVIA
estrogens, conjugated synthetic b
TABLET;ORAL021443-003May 10, 2004DISCNNoNo► Subscribe► SubscribeYY TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE
Teva Branded Pharm
ENJUVIA
estrogens, conjugated synthetic b
TABLET;ORAL021443-005Apr 27, 2007DISCNNoNo► Subscribe► SubscribeYY TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE
Teva Branded Pharm
ENJUVIA
estrogens, conjugated synthetic b
TABLET;ORAL021443-005Apr 27, 2007DISCNNoNo► Subscribe► SubscribeYY TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE
Teva Branded Pharm
ENJUVIA
estrogens, conjugated synthetic b
TABLET;ORAL021443-004May 10, 2004DISCNNoNo► Subscribe► SubscribeYY TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE
Teva Branded Pharm
ENJUVIA
estrogens, conjugated synthetic b
TABLET;ORAL021443-004May 10, 2004DISCNNoNo► Subscribe► SubscribeYY TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,855,703

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada2402559► Subscribe
Japan2011256181► Subscribe
South Korea100804224► Subscribe
South Korea20070045364► Subscribe
Japan2004500396► Subscribe
South Korea20030064614► Subscribe
European Patent Office1267852► Subscribe
Australia2001245417► Subscribe
Australia4541701► Subscribe
MexicoPA02008856► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Farmers Insurance
Boehringer Ingelheim
UBS
Citi
US Department of Justice
Dow
Federal Trade Commission
Express Scripts
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot